Esteve closes the Board of Directors renewal process with the appointment of Joan Esteve as a Chairman Blog Post

Esteve has just announced changes to its corporate governing bodies. In line with the plan approved by the Group’s Board, Albert Esteve will replace Joan Esteve as Chairman of the Board and announces the appointment of Staffan Schüberg, executive vicepresident of the Danish pharmaceutical company Lundbeckas, the group’s Chief Executive Officer. Since 2012, all discovery and preclinical development key units of Esteve are located at the Barcelona Science Park with the latest infrastructure and technology in a top-level academic and scientific environment in Spain.

 

IBEC researchers show that physical forces activate genes involved in cancer Blog Post

IBEC’s researchers at PCB, led by Pere Roca-Cusachs, reveal how forces trigger the expression of certain genes by increasing the activity of a protein called YAP in the nucleus of the cell.  The results of the study, published in Cell, have shown how these forces ‘switch on’ the expression of genes that may result in cancer.

 

Embryotools successfully concludes the first trials on an innovative assisted reproduction technique Blog Post

Embryotools —headquartered at Barcelona Science Park (PCB)— has successfully concluded tests on animal models to validate an innovative assisted reproduction technique known as Maternal Spindle Transfer (MST).  This new technique is a mitochondrial replacement therapy which groups of leading scientists from around the world are studying for the prevention of mitochondrial diseases, which are transmitted maternally and currently have no treatment. Embryotools has been working on this project for over three years in partnership with the PCB-PRBB Animal Facility Alliance and the company Reprogenetics UK, located at Oxford University.

 

An increase in low density lipoproteins would favour insulin resistance Blog Post

A study led by the University of Barcelona proved that low-density proteins (VLDL) can worsen insulin resistance, a disease that favours the development of type 2 diabetes. The study, published in the scientific journal Diabetologia , has been carried out by the research group led by Manuel Vázquez Carrera, researcher from the Department of Pharmacology, Toxicology and Therapeutic Chemistry and the Institute of Biomedicine of the UB (IBUB), located at the Barcelona Science Park.

 

Catalan biomedical companies attracted €153.1 million in investment in 2016 Blog Post

Catalan biomedical companies were able to attract €153.1 million in investment in 2016, a record figure for the sector. This is the main takeaway from the first Study on investment in the Biomedical industry in Catalonia 2017: Achievements and future challenges presented by CataloniaBio, based at the Barcelona Science Park, and EY at the Cercle d’Economia before some seventy members of the association, entrepreneurs, investors and other professionals. 

 

A pioneer project to promote organ donation in the European Union and neighbouring countries Blog Post

Raising awareness among society and promoting the training around highly specialized experts in the 28 member countries of the European Union and its neighbouring countries in the community area, aiming to improve the rate of organ donations are the main reference points for EUDONORGAN. This European project is led by the University of Barcelona (UB), together with Bosch i Gimpera Foundation (FBG) and the DTI Donation & Transplantation Institute, located at the Barcelona Science Park.

 

A team of UB and PCB takes part in the licence of a new technology of fluorescent dyes of biomedical interest Blog Post

A new article published in the journal Nature Protocols describes the new technology to develop a series of activable fluorophores that enable the peptide molecular labelling and improve cell-live imaging. The new study has the participation of the teams led by Rodolfo Lavilla, from the Faculty of Pharmacy and Food Sciences of the University of Barcelona and the Barcelona Science Park (PCB), and Marc Vendrell, from the Edinburgh Medical School (Scotland).